<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174211</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT Number: 2012-005500-18</org_study_id>
    <nct_id>NCT02174211</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.</brief_title>
  <acronym>VITCLEAR</acronym>
  <official_title>A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of pars plana vitrectomy on the intravitreal pharmacokinetics of&#xD;
      ranibizumab and to compare the half-life of ranibizumab and aflibercept.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, pharmacokinetic study comparing ranibizumab clearance in two&#xD;
      groups of patients; those with and without prior vitrectomy. Additionally it will compare&#xD;
      ranibizumab clearance to aflibercept clearance as well as the effect on systemic circulating&#xD;
      inflammatory and safety markers. Patients will already be receiving ranibizumab or&#xD;
      aflibercept therapy - the injection is itself administered irrespective of their&#xD;
      participation in this study and therefore this study will not alter medical management or the&#xD;
      choice of therapy.&#xD;
&#xD;
      To estimate ranibizumab and aflibercept clearance, it is important to measure serum&#xD;
      concentrations at several intervals within the first 24 hours. Participants will ideally have&#xD;
      venous blood sampling at the following times after their ranibizumab or aflibercept&#xD;
      injection:&#xD;
&#xD;
        -  1 hour&#xD;
&#xD;
        -  2 hours&#xD;
&#xD;
        -  3 hours&#xD;
&#xD;
        -  4 hours&#xD;
&#xD;
        -  6 hours&#xD;
&#xD;
        -  24 hours&#xD;
&#xD;
        -  2 days&#xD;
&#xD;
        -  4 days&#xD;
&#xD;
        -  1 week*&#xD;
&#xD;
        -  2 weeks&#xD;
&#xD;
        -  4 weeks*&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ranibizumab half-life</measure>
    <time_frame>12 Months</time_frame>
    <description>Vitrectomised and non-vitrectomised patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aflibercept half-life</measure>
    <time_frame>12 Months</time_frame>
    <description>Non-vitrectomised patients only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sub-group analysis of the effect of PVD on ranibizumab half-life</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of half-life (drug assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ranibizumab and aflibercept concentrations on serum inflammatory and safety marker levels.</measure>
    <time_frame>12 months</time_frame>
    <description>Assay levels of cytokines and inflammatory/safety markers</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Arm A: Ranibizumab (Lucentis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Previous Vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Ranibizumab (Lucentis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-vitrectomised, PVD / no PVD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Aflibercept (Eylea)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-vitrectomised, PVD / no PVD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal injection of ranibizumab</description>
    <arm_group_label>Arm A: Ranibizumab (Lucentis)</arm_group_label>
    <arm_group_label>Arm B: Ranibizumab (Lucentis)</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal injection of aflibercept</description>
    <arm_group_label>Arm C: Aflibercept (Eylea)</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Adults of either sex aged 55 years and older&#xD;
&#xD;
          -  Active neovascular AMD in the study eye&#xD;
&#xD;
          -  Intravitreal dose of 0.5 mg ranibizumab or 2 mg aflibercept required, as per current&#xD;
             clinical guidelines&#xD;
&#xD;
          -  Venous access that is sufficient to allow easy blood sampling on a frequent basis&#xD;
&#xD;
          -  Able to give written consent&#xD;
&#xD;
          -  Willingness to comply with all study procedures&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Myopia greater than 8 dioptres in the study eye&#xD;
&#xD;
          -  Axial length of eye under 20mm or over 26mm&#xD;
&#xD;
          -  Aphakia in study eye&#xD;
&#xD;
          -  Pseudophakia with a defect in the posterior capsule&#xD;
&#xD;
          -  Glaucoma in study eye&#xD;
&#xD;
          -  Current renal dialysis&#xD;
&#xD;
          -  Presence of inflammatory eye conditions, such as uveitis, or systemic conditions&#xD;
             likely to elevate CRP.&#xD;
&#xD;
          -  Intraocular surgery within 6 months of enrolment, except for routine&#xD;
             phacoemulsification cataract surgery that may occur within 4 months of enrolment&#xD;
&#xD;
          -  Current treatment for wet age-related macular degeneration with an intravitreal agent&#xD;
             other than ranibizumab or aflibercept in the study eye. Patients expected to change&#xD;
             their anti-VEGF agent during the sampling period are also excluded.&#xD;
&#xD;
          -  Known significant allergy to ranibizumab or aflibercept&#xD;
&#xD;
          -  Participants who, in the opinion of the Investigator, would not be willing or able to&#xD;
             comply with the study protocol or provide informed consent.&#xD;
&#xD;
          -  Patients with severe anaemia&#xD;
&#xD;
          -  Patients who have received anti-VEGF therapy in either eye within 8 weeks of&#xD;
             enrolment, or who are likely to require anti-VEGF treatment in the fellow eye during&#xD;
             the course of venous sampling. Note that the final venous sample at 4 weeks can be&#xD;
             undertaken on the same day as an anti-VEGF injection, but must be taken prior to any&#xD;
             injection.&#xD;
&#xD;
          -  Patients presently taking any topical (skin or eye), periocular, intraocular, local or&#xD;
             systemic treatment with immunosuppressive or anti-inflammatory agents, such as&#xD;
             steroids, steroid sparing agents, and NSAIDs. Patients who have received any of these&#xD;
             agents within 2 months prior to enrolment are also excluded, as are those thought&#xD;
             likely to receive these medications during the course of venous sampling.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy L Jackson, PhD,FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The Investigator(s) shall permit trial-related monitoring, audits, REC review, and regulatory inspections (where appropriate) by providing direct access to source data and other documents (i.e. patients' case sheets, blood test reports, X-ray reports, histology reports etc). Where necessary, inspection may also take place at the site's facilities.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

